ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
29 Aprile 2024 - 10:05PM
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma
company focused on accelerating the development and delivery of
transformative medicines in immunology, today announced it will
host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to
discuss its first quarter 2024 financial results and provide a
corporate update.
A live webcast of the conference call will be
available on the Company’s website under Events &
Presentations. A replay of the webcast will be available on the
Company’s website for 90 days.
About ACELYRIN, INC.ACELYRIN,
INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical
biopharma company – with additional operations in the San Francisco
Bay area – focused on providing patients life-changing new
treatment options by identifying, acquiring, and accelerating the
development and commercialization of transformative medicines.
ACELYRIN has two programs in late-stage clinical development.
Izokibep is a next generation inhibitor of IL-17A in Phase 3
development for the treatment of psoriatic arthritis, hidradenitis
suppurativa and uveitis. Lonigutamab is a subcutaneously delivered
monoclonal antibody targeting IGF-1R being investigated for the
treatment of TED.
For more information about ACELYRIN, visit us at
www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking StatementsSome
statements in this press release are, or may be considered,
forward-looking statements, including statements regarding
ACELYRIN’s progress, business plans and clinical trials, as well as
the potential future benefits of our product candidates. While
ACELYRIN, INC. considers any projections to be based on reasonable
assumptions, these forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ
materially from those anticipated in such forward-looking
statements.
ACELYRIN
Contacts:investors@acelyrin.commedia@acelyrin.com
Grafico Azioni ACELYRIN (NASDAQ:SLRN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni ACELYRIN (NASDAQ:SLRN)
Storico
Da Dic 2023 a Dic 2024